Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Ipilimumab + Nivolumab & Colorectal cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)), on April 8, 2025, the Food and Drug Administration granted approval for the combination of nivolumab and ipilimumab to be used in adult and pediatric patients aged 12 and older who have unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). Additionally, the FDA transitioned the accelerated approval of nivolumab as a single agent to regular approv…